Vireo GrowthFRA:K95 -5.39%44 Quick Ratio is 0.84 as of Mar. 2026, which is 36% below its 10-year median of 1.31. GuruFocus rates FRA:K95 with a GF Score™ of 44/100 and a GF Value™ of €7.54 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 997 Drug Manufacturers companies, Vireo Growth ranks worse than 74.02% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Vireo Growth's quick ratio for the quarter that ended in Mar. 2026 was 0.84.
Vireo Growth has a quick ratio of 0.84. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Vireo Growth's Quick Ratio or its related term are showing as below:
FRA:K95'
s Quick Ratio Range Over the Past 10 Years
Min: 0.04 Med: 1.31 Max: 57.25
Current: 0.84
During the past 13 years, Vireo Growth's highest Quick Ratio was 57.25. The lowest was 0.04. And the median was 1.31.
FRA:K95's Quick Ratio is ranked worse than 74.02% of 997
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs FRA:K95: 0.84
Vireo Growth (FRA:K95) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Vireo Growth Quick Ratio Related Terms
Vireo Growth Quick Ratio Historical Data
* Premium members only.
The historical data trend for Vireo Growth's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vireo Growth's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vireo Growth Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vireo Growth's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Vireo Growth's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Vireo Growth's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vireo Growth (FRA:K95) has a Quick Ratio of 0.84 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Vireo Growth and its competitors. This is 36% below median its historical median of 1.31. Over the past decade, Vireo Growth's Quick Ratio has ranged from 0.04 to 57.25. According to the industry distribution chart, Vireo Growth ranks #738 out of 997 companies in the Drug Manufacturers industry, placing it in the top 74%.
Is Vireo Growth's Quick Ratio too high?
Vireo Growth's current Quick Ratio of 0.84 is 36% below median its 10-year median of 1.31. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 57.25. The Drug Manufacturers industry median Quick Ratio is 1.45. Vireo Growth's value of 0.84 is 42.1% below this industry median. Based on the distribution chart, Vireo Growth ranks #738 out of 997 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Vireo Growth has a GF Score™ of 44/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vireo Growth's Quick Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vireo Growth ranks #738 out of 997 companies for Quick Ratio. This places Vireo Growth in the lower half of its industry. The industry median Quick Ratio is 1.45. Vireo Growth's value of 0.84 is 42.1% below this benchmark. Historically, Vireo Growth's own Quick Ratio has ranged from 0.04 to 57.25 over the past decade. While the company's 10-year median is 1.31 vs. the industry median of 1.45, Vireo Growth has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vireo Growth's current Quick Ratio of 0.84 is 42.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Vireo Growth and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vireo Growth's current Quick Ratio is 0.84, which is 36% below median its own 10-year median of 1.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vireo Growth stock overvalued right now?
Based on GuruFocus' analysis, Vireo Growth (FRA:K95) is currently considered Modestly Overvalued. The stock's GF Value™ is €7.54, compared to a current price of €8.42 — trading 11.7% above its estimated fair value. The current Quick Ratio is 0.84, which is 36% below median its 10-year median of 1.31 and 42.1% below the Drug Manufacturers industry median of 1.45. Vireo Growth's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Vireo Growth (FRA:K95), the current Quick Ratio is 0.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vireo Growth (FRA:K95) Overvalued in 2026?
Based on GuruFocus' analysis, Vireo Growth stock appears to be overvalued.
The current stock price of €8.42 is trading 11.7% above its estimated GF Value™ of €7.54.
GuruFocus considers Vireo Growth to be Modestly Overvalued.
Key valuation signals for FRA:K95:
Quick Ratio: 0.84 (36% below median its 10-year median of 1.31)
GF Value™: €7.54 vs. price of €8.42 (11.7% above fair value)
Industry Position: 42.1% below the Drug Manufacturers median (#738 of 997)
No single metric tells the full story. See the FRA:K95 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vireo Growth Incis a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. The company operates in one single segment.
44GF Score
Get the complete analysis for FRA:K95
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:K95 has been successfully added to your 
